A multicenter retrospective study evaluated the efficacy of Tα1 for critical COVID-19 patients, and the results suggested that treatment with Tα1 could markedly decrease 28-day mortality and attenuate acute lung injury in critical type of COVID-19 patients (27). Here, TAAR1 is linked to COVID-19.